← back to search

Yujun Dong

Hebei Medical University · CN
Area of research
Hematology · Pathology and Forensic Medicine
Research interest
Research interests include Multiple Myeloma Research and Treatments, Acute Myeloid Leukemia Research, Hematopoietic Stem Cell Transplantation, and Lymphoma Diagnosis and Treatment.
h-index
15
citations
806
works
156
NIH funding
primary concept
email

Recent publications

Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type
Human Genomics 2025cited by 4position: lastdoi
Development and validation of a prognostic staging system for primary plasma cell leukemia
Journal of Hematology & Oncology 2025cited by 2position: middledoi
[Severe pneumonia, intracranial infection, and reversible splenial lesion syndrome caused by <i>chlamydia psittacosis</i> infection].
PubMed 2025cited by 1position: middledoi
Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study
Blood 2025cited by 0position: middledoi
Asymptomatic multicentric Castleman disease: a potential early stage of idiopathic MCD
Blood Advances 2024cited by 5position: middledoi
Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd
Blood 2024cited by 0position: middledoi
Real‐world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis
Cancer Medicine 2023cited by 14position: middledoi
684P Phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC)
Annals of Oncology 2023cited by 11position: middledoi
The R2-ISS in a Multicenter Cohort of Chinese Patients With Newly Diagnosed Multiple Myeloma
HemaSphere 2023cited by 9position: middledoi
Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment
Blood Advances 2023cited by 5position: middledoi
Autologous hematopoietic stem cell transplantation improves survival outcomes in peripheral T-cell lymphomas: a multicenter retrospective real-world study
Annals of Hematology 2023cited by 2position: middledoi
441P The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Annals of Oncology 2023cited by 2position: middledoi
Comprehensive Analysis of Baseline Risk Factors Associated with Poor Outcomes and Development of the First Staging System for Primary Plasma Cell Leukemia: A Retrospective, Multicenter, Cohort Study
SSRN Electronic Journal 2023cited by 0position: middledoi
Oligosecretory Waldenström macroglobulinemia exhibits excellent treatment response and outcomes
Haematologica 2023cited by 0position: middledoi
Lymph Node Fibroblastic Reticular Cells Attenuate Immune Responses Through Induction of Tolerogenic Macrophages at Early Stage of Transplantation
Transplantation 2022cited by 5position: middledoi
The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma
Blood Cancer Journal 2022cited by 5position: middledoi
A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe
Blood 2022cited by 1position: middledoi
Oligosecretory Waldenström Macroglobulinemia Patients Exhibit Excellent Treatment Response and Outcomes
Blood 2022cited by 0position: middledoi
Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study
Blood 2022cited by 0position: middledoi
Waldenström's Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals
Blood 2020cited by 1position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Weiling Xu · Jilin University2 papers (2022–2023)Fengyan Jin · Jilin University2 papers (2022–2023)Yun Dai · Shandong University2 papers (2022–2023)Shanshan Yu · Jilin University2 papers (2022–2023)Xinyue Liang · Shanghai University2 papers (2022–2023)Yanping Ma · Shanxi Medical University2 papers (2022–2023)Guangxun Gao · State Council of the People's Republic of China2 papers (2022–2023)Mengyao Li · Tianjin University of Traditional Chinese Medicine2 papers (2022–2023)Fan Zhou · Queen's University2 papers (2022–2023)Pei‐Yu Yang · Fudan University2 papers (2022–2023)Hanyun Ren · Peking University2 papers (2022–2025)Xiaoqi Qin · Shanxi Medical University2 papers (2022–2023)Hua Xue · Affiliated Hospital of Hebei University2 papers (2022–2023)Wenrong Huang · Nanchang University2 papers (2023–2023)Cheng Huang · Fujian Medical University1 papers (2023–2023) · 1 papers (2023–2023)Kun Yi · Nanchang University1 papers (2023–2023)Fei Dong · Jinan University1 papers (2023–2023)Weiping Liu · Donghua University1 papers (2023–2023) · 1 papers (2025–2025)